TL;DR
The oral GLP-1 market is no longer Novo's to lose: Lilly's Foundayo has taken more than 30% of new U.S. oral obesity patients, and the pricing floor has collapsed to $149–$299 per month on the live TrumpRx channel ahead of Novo's scheduled $675 list-price cut on January 1, 2027. Meanwhile, the challengers are converging on the same wedge — less-frequent dosing — with Amgen launching a Phase 3 switch study straight off weekly Zepbound and Wegovy, and Viking's maintenance readout due this quarter. Novo's September 21 capital markets day, happening as this digest closes, is the pivot point for whether the "third leg" investors are demanding materializes.
The Oral Land Grab: Foundayo Closes the Gap
The once-a-day oral battle between Lilly and Novo has narrowed from a blowout to a genuine contest, and the Medicare bridge is quietly expanding the whole category.
"Eli Lilly on Monday said it has captured more than 30% of new patients in the U.S. market for oral obesity treatments, narrowing the early lead gained by Danish rival Novo Nordisk with its Wegovy pill." — Reuters, Sept 14, 2026
The weekly script tape backs the claim: per Fierce Pharma's tracker, the Wegovy pill fell roughly 12% sequentially to about 161K scripts after Labor Day while Foundayo dipped just 1% to more than 47K — its second-best week ever (Fierce Pharma Oral GLP-1 Tracker). That's a long way from Novo CEO Mike Doustdar's August claim that the Wegovy pill held "about 90%" of the oral market. Just as important, Lilly's Ilya Yuffa said 60–70% of patients in the $50 co-pay Medicare pilot are new to GLP-1 therapy — the orals are recruiting new-to-class patients, not cannibalizing injectables (Reuters).
What to watch: Whether Novo's capital markets day produced a credible counter-narrative on oral Wegovy scale-up — and whether Foundayo's ramp holds above 50K weekly scripts.
Novo's Third-Leg Problem: IL-6 Dies, Patience Runs Out
Novo's diversification story took a body blow just as investors gathered to demand a new one.
"Novo suffered a major setback after halting trials of its experimental heart drug, ziltivekimab. This compounded concerns about Novo's long-term sales growth as the clock ticks down on patent protection." — Reuters, Sept 21, 2026
The HERMES and ATHENA Phase 3 terminations on September 8, following the ZEUS failure, effectively close the book on IL-6 as a cardiovascular target (NVO market view). Morgan Stanley's September 12 downgrade to Sell cited share losses to Lilly over the next 18 months plus the patent cliff, and the numbers are brutal: Zepbound sales are expected to outpace Wegovy this year by more than $7 billion, per LSEG. Union Investment's Markus Manns put the investor mood plainly: "They should work harder in building a third leg ... because in diabetes and obesity, they won't find enough growth opportunities." The counterpoints — Wegovy's first-in-class MASH approval in China and a pediatric trial where 40.4% of children were no longer classified with obesity — are real but not narrative-changing (NVO market view
).
What to watch: The capital markets day outcomes — new medium-term targets, zenagamtide-vs-CagriSema prioritization, and any M&A signals (Doustdar told the FT he would "not shy away" from deals larger than Pfizer's $10B Metsera buy).
The Dosing Wedge: Amgen and Viking Attack the Weekly Injection
The most interesting competitive strategy this cycle isn't another me-too weekly injectable — it's making weekly injections obsolete.
"MARITIME-SWITCH, a Phase 3 study of MariTide, was initiated in adults living with obesity or overweight who will be switching from weekly tirzepatide or weekly semaglutide to MariTide on an every eight-week or quarterly dosing schedule." — Synapse (PatSnap) MariTide profile
Amgen is recruiting directly from the installed base of Zepbound and Wegovy patients — if the switch works without efficacy loss, MariTide enters with a dosing advantage no incumbent offers (ClinicalTrials.gov NCT07575399). Viking is running the same play from the other direction: CEO Brian Lian reaffirmed at the Morgan Stanley conference that the VK2735 maintenance study — testing every-other-week, monthly, and oral transition dosing — reads out this quarter, with success defined as keeping patients "within 75% of the weight loss that they had achieved at week 21" (Investing.com transcript). The options market is treating it as a binary, with heavy call volume and a negative 90/110 skew (VKTX market view).
What to watch: Viking's maintenance readout this quarter — a weak result would undercut the flexible-dosing thesis right before its oral Phase 3 start.
The Pricing Reset Is Now, Not Coming
The gap between sticker price and street price has become a chasm, and the list-price cut is scheduled, not hypothetical.
"Novo Nordisk announced it will slash list prices for Ozempic, Rybelsus, and Wegovy to $675 for a one-month supply effective Jan. 1, 2027." — GLPcompare price tracker
The cash channel is already far below that: TrumpRx is live at $149/month for the Wegovy pill and $299 for Zepbound (trumprx.gov), Medicare prices are set at $245 under the MFN deal (White House fact sheet), and physician Holly Lofton reports self-pay rates "as low as $150 a month" versus close to $1,500 for injectables a year ago (AJMC). The reset is asymmetric: Lilly's small-molecule Foundayo has structurally lower manufacturing costs, while Novo is cutting list into a 2027 where its oral must defend share — and a Reuters-reported study showing low-dose tirzepatide beating low-dose semaglutide (5.5% vs 2.2% weight loss over a year) suggests cheaper, lower-dose regimens could stretch supply further (Yahoo Finance/Reuters).
What to watch: Whether the January 1, 2027 list-price cut lands as scheduled, and how employer/insurer coverage economics respond to a $149–$299 cash channel that undercuts traditional formulary math.
What surprised us
- Great clinical data no longer re-rates an obesity biotech. Structure Therapeutics reported up to 16.2% weight loss at 72 weeks with no plateau and under 5% discontinuation — and the stock fell 14.7% that day, now down 30.7% in a month (Seeking Alpha). In a market where Lilly and Novo orals are already scaling, differentiation has to be commercial, not just clinical.
- The ad lawsuit is a proxy war over the efficacy gap. Novo's preliminary-injunction motion targets only Lilly's comparative claims — not Lilly's ability to sell — because the head-to-head data itself is the problem Novo can't litigate away (MobiHealthNews).
- Amgen's stock fell ~10% this month for reasons that have nothing to do with obesity — Novartis' failed Lp(a) trial spooked investors about Amgen's own cardiology program (Seeking Alpha), even as the MariTide switch study quietly advanced.
Open threads worth a vote
- Novo Nordisk Capital Markets Day outcomes (London, Sept 21, 2026) — new targets, pipeline prioritization, and M&A appetite were all on the table; next cycle's digest should pick up what was announced.